Welcome to our dedicated page for FSD Pharma Class B Subordinate Voting Shares news (Ticker: $HUGE), a resource for investors and traders seeking the latest updates and insights on FSD Pharma Class B Subordinate Voting Shares stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect FSD Pharma Class B Subordinate Voting Shares's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of FSD Pharma Class B Subordinate Voting Shares's position in the market.
FSD Pharma, a biopharmaceutical company, has submitted a Phase-1 clinical trial application for Lucid-21-302 in Australia. Lucid-21-302 is a neuroprotective compound for the treatment of multiple sclerosis, showing promise in preclinical models. The company aims to advance Lucid-21-302 into a phase-2 clinical trial, with optimism about its potential as a treatment for MS.
FSD Pharma signed an agreement with Applied Science and Performance Institute (ASPI) to conduct a clinical trial in the United States to assess the safety and efficacy of unbuzzd(TM) in an induced state of alcohol intoxication. The trial will compare the effects of unbuzzd(TM) to a placebo in thirty healthy volunteers. FSD Pharma aims to establish itself as a leader in products targeting alcohol intoxication.